NEW YORK (GenomeWeb News) – Cancer genetics diagnostic company NeoGenomics today reported flat revenues for the second quarter, as changes to Medicare's reimbursement for molecular diagnostics negatively impacted operations.

The Fort Myers, Fla.-based company said that revenues for the three months ended June 30 totaled $15.6 million, the same as a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.